What went well
- A March 18, 2026 independent Data Safety Monitoring Board (DSMB) review of the ongoing ABTECT-UC Phase 3 maintenance trial found no new safety signals, with the analysis covering 100% of randomized patients and nearly 90% having completed the 44-week double-blind period - a key de-risking update ahead of the topline readout.
- The maintenance trial remained on track to report topline results in late Q2 2026, with an NDA submission for obefazimod in UC targeted for Q4 2026 (subject to positive data).
- Abivax ended 2025 with cash, cash equivalents and short-term investments of EUR 530.4 million, supporting a cash runway into Q4 2027, and had settled all of its structured debt during the year (Kreos, Claret and the Heights convertible notes).
- The company built out a commercial and senior leadership team for launch readiness: it appointed Michael Nesrallah as Chief Commercial Officer (ex-Takeda IBD/Entyvio leader), Keith Fournier as SVP Global Regulatory Affairs, and Maurus de la Rosa as SVP Research.
What went wrong
- Full-year net loss widened sharply to EUR 336.1 million (from EUR 176.2 million in 2024), reflecting both higher operating spend and large non-cash financial charges.
- Operating loss increased to EUR 246.1 million (from EUR 173.0 million), with R&D up EUR 31.2 million to EUR 177.8 million (CMC/supply-chain build-out +EUR 13.0M, Crohn's Phase 2b +EUR 10.2M, new indications/combination +EUR 4.1M, UC Phase 3 +EUR 1.6M).
- G&A more than doubled to EUR 67.7 million (from EUR 32.9 million), driven by EUR 33.4 million higher personnel costs - chiefly EUR 27.3 million of employer taxes and social contributions on French AGA plans caused by the second-half share-price surge.
- The full-year net financial loss was EUR 84.2 million, including non-cash fair-value increases on the Heights notes (EUR 36.0 million) and Kreos/Claret warrants (EUR 29.9 million), EUR 17.2 million of royalty-certificate interest, plus EUR 5.8 million of deferred income tax.
- Cash flow used in operating activities rose to EUR 161.1 million (from EUR 154.1 million).
- Board and management transitions: Sofinnova Partners (represented by Dr. Kinam Hong) stepped down from the Board on March 19, 2026, and long-serving Chief Scientific Officer Didier Scherrer announced his departure after 17 years.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| ABTECT Phase 3 maintenance topline | late Q2 2026 | On track for late Q2 2026 (DSMB found no new safety signals on March 18, 2026) |
| Phase 2b induction trial for Crohn's disease (ENHANCE-CD) | Q4 2026 | Completion expected Q4 2026 |
| NDA submission (obefazimod in UC) | Q4 2026 | Targeted Q4 2026, subject to positive data |
| Cash runway | from Dec 31, 2025 | Into Q4 2027 (EUR 530.4M cash, equivalents and short-term investments) |
| Next reporting dates | 2026 | AGM May 11, 2026; Q1 2026 results May 25, 2026 |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| R&D costs (FY) | EUR 177.8M (+EUR 31.2M) | CMC/supply chain, Crohn's Phase 2b, new indications/combination therapy and UC Phase 3; 96.5% of R&D related to obefazimod. |
| G&A costs (FY) | EUR 67.7M (vs EUR 32.9M) | EUR 27.3M of employer taxes/social contributions on AGAs from the second-half share-price surge. |
| Operating loss (FY) | EUR 246.1M (vs EUR 173.0M) | Higher R&D and G&A; operating income of EUR 4.6M. |
| Net financial loss (FY) | EUR 84.2M (vs EUR 3.3M) | Non-cash fair-value increases on convertible notes and warrants, royalty-certificate interest and FX. |
| Net loss (FY) | EUR 336.1M (vs EUR 176.2M) | Wider operating loss, EUR 84.2M financial loss and EUR 5.8M deferred tax. |
| Cash, equivalents & short-term investments | EUR 530.4M at Dec 31, 2025 | July 2025 offering net proceeds (~EUR 597.2M) less full-year operating use (EUR 161.1M) and debt repayment; total equity EUR 455.2M. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Launch readiness / leadership build-out | - | Appointed Chief Commercial Officer Michael Nesrallah plus SVPs of Global Regulatory Affairs and Research to prepare for potential obefazimod commercialization. | — |
| ABTECT maintenance de-risking | Induction positive | March 2026 DSMB found no new safety signals with ~90% of patients through the 44-week period; topline due late Q2 2026. | — |
| Non-cash-driven losses | - | AGA-related employer charges (EUR 27.3M) and convertible/warrant fair-value moves inflated reported FY loss to EUR 336.1M despite a strengthened balance sheet. | — |
| Board/management transitions | - | Sofinnova (Kinam Hong) stepped down; CSO Didier Scherrer departing after 17 years. | — |
More on Abivax S.A.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.